Viracta Therapeutics, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Viracta Therapeutics, Inc. (Nasdaq: VIRX) operates as a clinical-stage precision oncology company focused on developing therapies for virus-associated cancers, particularly those linked to the Epstein-Barr virus (EBV); its lead product candidate is Nana-val, an all-oral combination therapy of proprietary investigational histone deacetylase (HDAC) inhibitor nanatinostat and antiviral valganciclovir utilizing a proprietary "Kick & Kill" approach to target EBV-positive relapsed/refractory lymphomas including peripheral T-cell lymphoma (PTCL), with additional pipeline exploration in EBV-positive solid tumors such as nasopharyngeal carcinoma and gastric carcinoma, and legacy assets including vecabrutinib, an investigational BTK inhibitor acquired for lymphoma and chronic lymphocytic leukemia; the company targets patients worldwide with limited treatment options in this oncology niche. Founded in 2007 and headquartered in Cardiff-by-the-Sea, California, Viracta resulted from a 2021 merger with Sunesis Pharmaceuticals that provided initial funding runway into 2024 and established operations in San Diego. In recent major changes, the company closed its pivotal Phase 2 NAVAL-1 trial for Nana-val in December 2024, announced a wind down of operations on February 5, 2025, ceased active operations with inquiries redirected to [email protected], implemented a 42% workforce reduction and Board resize to six members in November 2024, and explored strategic alternatives amid cash constraints.
Viracta Therapeutics Announces Wind Down of Operations
Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives
Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Here's Why Sunesis (VIRX) Is a Great 'Buy the Bottom' Stock Now
Why Is Viracta Therapeutics (VIRX) Stock Up 42% Today?
Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan
Viracta Therapeutics Announces New Employment Inducement Grants
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer
Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
3 Speculative Penny Stocks Offering High-Upside Potential for Under a Buck
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Viracta Therapeutics Provides Clinical Update and Outlook for 2024
Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma
Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels